EHI
AVTX icon

Eagle Health Investments’s Avalo Therapeutics AVTX Stock Holding History

Eagle Health Investments’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.34M Buy
+235,093
New +$3.72M 0.72% 22

Other funds holding AVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Eagle Health Investments's AVTX Position: Q2 2026 in Review

Eagle Health Investments opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 235,093 shares worth $4.34M. The stake represents 0.72% of the portfolio and ranks #22 among its holdings.

29 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Eagle Health Investments held 235,093 shares of Avalo Therapeutics worth $4.34M as of Q2 2026.
  • Avalo Therapeutics was a new Eagle Health Investments position in Q2 2026.
  • Avalo Therapeutics made up 0.72% of Eagle Health Investments's portfolio in Q2 2026, its #22 holding.
  • 29 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.